Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
345 Results for "
Btk
" in MedChemExpress (MCE) Product Catalog:
Products (345)
345 Results for "Btk" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA) .
1
1 Cited Publications
TL12-186 is a multi-kinase PROTAC degrader. TL12-186 recruits the CRBN E3 ubiquitin ligase to target and degrade a variety of distinct kinases, including FLT3, BTK, AURKA, PTK2B, and multiple cyclin-dependent kinases (CDKs). TL12-186 can be used in leukemia-related research .
1
1 Cited Publications
Target:
Research Areas:
1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker. 1,2-Bis(2-iodoethoxy)ethane can be used in the synthesis of MT802 (HY-122562) and SJF620 (HY-133137). MT-802 and SJF620 are potent PROTAC BTK degraders with DC50s of 1 nM and 7.9 nM, respectively .
1
1 Cited Publications
Cat. No.: HY-163638
CAS No.: 3094209-54-5
Research Areas:
BRD4 degrader-1 (Compound mL 1-50) is a relatively selective, monovalent and covalent BRD4 Molecular glue degrader. BRD4 degrader-1 induces degradation of both long and short isoforms of BRD4 by targeting DCAF16 (an E3 ligase). BRD4 degrader-1 can be used in breast cancer research .
Cat. No.: HY-160141
CAS No.: 2736508-60-2
Synonyms: BGB-16673; Btk-IN-29
Research Areas:
BGB-16673 (BGB-16673) is an orally active, selective BTK PROTAC degrader (IC50=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .
Synonyms: SNS062 analog
Target:
Research Areas:
BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM.
Cat. No.: HY-49421
CAS No.: 1791402-91-9
Research Areas:
BTK ligand 12 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). BTK ligand 12 can serve as an active control for the target protein ligand of NRX-0492 (HY-153357) .
Cat. No.: HY-128403
CAS No.: 2230724-66-8
Target:
Research Areas:
BTK inhibitor 8 (Compound 27) is a Btk inhibitor with an IC50 of 0.11 nM. BTK inhibitor 8 inhibits Btk activity. BTK inhibitor 8 suppresses B cell activation. BTK inhibitor 8 is applicable to research related to arthritis and asthma .
Target:
Research Areas:
Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.
Cat. No.: HY-130255
CAS No.: 2376726-26-8
Target:
Research Areas:
BTK inhibitor 13 is an orally active Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 value of 1.2 nM against human BTK. BTK inhibitor 13 covalently modifies the Cys481 residue of BTK when binding to the inactive conformation of BTK. BTK inhibitor 13 is used for the research of autoimmune diseases .
Cat. No.: HY-152212
CAS No.: 1374240-01-3
Target:
Research Areas:
BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM .
Cat. No.: HY-168302
Research Areas:
BTK ligand 10 is the ligand of BTK. BTK ligand 10 can be used to synthesize NX-2127 (HY-153220) .
Cat. No.: HY-176381
CAS No.: 2250382-80-8
Research Areas:
BTK ligand 11-alcohol-PEG6-azido is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as TDP-43 degrader-1 (HY-122828) .
Target:
Research Areas:
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .
Cat. No.: HY-147584
CAS No.: 2764674-60-2
Target:
Research Areas:
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .
Cat. No.: HY-179076
CAS No.: 1791402-90-8
Research Areas:
BTK/IKZF1/3 ligand 1 is a BTK/IKZF1/3 PROTAC ligand. BTK/IKZF1/3 ligand 1 can be conjugated with E3 ligase Ligand (HY-41547) and linker to synthesize PROTAC BTK/IKZF1/3 Degrader-1 (HY-179077). PROTAC BTK/IKZF1/3 Degrader-1 can be used for cancer research .
Cat. No.: HY-179562
CAS No.: 2649400-05-3
Target:
Research Areas:
BTK degrader-2 (Example 2) is a dual-functional BTK molecular glue degrader, which causes the degradation of BTK through the ubiquitin-proteasome pathway. BTK degrader-2 can be used for the study of B-cell-related diseases .
Cat. No.: HY-148832
CAS No.: 1581714-50-2
Target:
Research Areas:
BTK-IN-20 (compound 283) is a BTK tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
